A novel drug-delivery system has demonstrated effectiveness in treating specific bladder cancer patients whose tumors previously did not respond to conventional therapies.

TAR-200 was found to eliminate tumors in 82% of patients participating in a phase 2 clinical trial for people with high-risk nonmuscle-invasive bladder cancer whose disease was previously resistant to treatment. Approximately 70% of new cases of bladder cancer are classified as nonmuscle invasive.

The impressive results of the SunRISe-1 trial, published in the Journal of Clinical Oncology in September, suggest a significant treatment advance for how certain types of bladder cancer might be treated.

“Traditionally, these patients have had very limited treatment options,” Sia Daneshmand, M.D., director of urologic

See Full Page